Clinical Trials Logo

Filter by:
NCT ID: NCT02832687 Terminated - Clinical trials for Recovery Following Cholecystectomy

Multi-dose Acetaminophen for Patients Undergoing General Anesthesia

Start date: June 19, 2017
Phase: Phase 4
Study type: Interventional

Study Objective The aim of the proposed study is to examine the effect of Q4 hour multidose IV acetaminophen on patients' readiness for discharge. In doing so the investigators will also investigate the various factors that could potentially contribute to a patient's readiness for discharge such as overall opioid consumption, time to rescue medication, incidence of postoperative nausea and vomiting, pain scores, and perioperative stress markers and their overall correlation with IV acetaminophen intake.

NCT ID: NCT02831933 Terminated - Clinical trials for Metastatic Uveal Melanoma

Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal Melanoma

ENSIGN
Start date: February 15, 2017
Phase: Phase 2
Study type: Interventional

This is a Phase II trial to determine the efficacy and safety of in situ gene therapy and stereotactic body radiation therapy (SBRT) used as a window of opportunity treatment before nivolumab in patients with metastatic squamous or non-squamous non-small cell lung carcinoma (NSCLC) and metastatic uveal melanoma. In situ gene therapy will consist of adenovirus-mediated expression of herpes simplex virus thymidine kinase (ADV/HSV-tk) plus Valacyclovir therapy.

NCT ID: NCT02831387 Terminated - Dry Eye Disease Clinical Trials

Evaluation of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease

Start date: July 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the effect of treatment with 0.017% P-321 on Dry Eye Symptoms.

NCT ID: NCT02830438 Terminated - Clinical trials for Chronic Kidney Disease

Shear Wave Elastography in Native Kidney Disease

Start date: July 1, 2016
Phase: N/A
Study type: Interventional

In this proposal, the aim is to examine shear wave elastography (SWE) measurements in diseased native kidneys and correlate them with grades of fibrosis using histological samples. The overall goals of the proposed study are addressed by the following specific aim. Specific aim: To determine whether differences exist in elasticity measurements between native kidneys with and without fibrosis. Hypothesis: Kidneys with higher grades of fibrosis will demonstrate higher measures of tissue elasticity and stiffness compared to kidneys with zero fibrosis.

NCT ID: NCT02830334 Terminated - Children Clinical Trials

Use of the Ask Suicide-Screening Questions (ASQ) in Pediatric Outpatient Settings

Start date: July 9, 2016
Phase:
Study type: Observational

Background: Doctors and nurses who work in non-mental health settings need ways to know when patients are at risk. Researchers created the Ask Suicide-Screening Questions (ASQ) to be used in an emergency department for children. This is a 4-item suicide risk screening tool. We wanted to see if this is also a good tool to use in the outpatient setting. Two studies are being done to test it at hospitals. This study is for researchers to analyze the data from those two studies. Objectives: To combine and analyze data from two studies to see how well the ASQ can detect suicide risk in pediatric outpatient clinics. Eligibility: No people are enrolled in this study. Design: Participants in the two non-NIH studies will give consent for their data to be shared. The data will be confidential and secure. They will have no personal information attached to them. Researchers will get the data and analyze them.

NCT ID: NCT02830087 Terminated - Clinical trials for Knee Arthroplasty, Total

Tourniquet Pressure in Primary Total Knee Arthroplasty

Start date: June 2016
Phase: N/A
Study type: Interventional

This proposed novel randomized control trial (RCT) seeks to address this gap in TKA protocol by gaining a better understanding of the relationship between tourniquet pressure and time, and intraoperative performance and post-operative outcomes. This study does not seek to answer the question of "tourniquet vs no tourniquet", but to seek a tourniquet usage that would maximize the intraoperative benefits for the surgeon and minimize the negative consequences for patient outcomes. Specific Aim #1: enroll around 146 primary TKA patients. Specific Aim #2: evaluate different tourniquet cuff pressures (TCP) and tourniquet times in relation to intraoperative performance. Specific Aim #3: evaluate different TCP and tourniquet times in relation to post-operative pain and complications of short-term, intermediate, and long-term followup. Specific Aim #4: evaluate different TCP and tourniquet times in relation to post-operative function of short-term, intermediate, and long-term followup.

NCT ID: NCT02829814 Terminated - Fibromyalgia Clinical Trials

Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia

RE-AFFIRM
Start date: July 2016
Phase: Phase 3
Study type: Interventional

The present trial is designed to assess the safety and efficacy of TNX-102 SL 2.8 mg tablets, taken daily at bedtime after 12 weeks of treatment in patients with fibromyalgia. The use of low-dose sublingual formulation of cyclobenzaprine (TNX-102 SL) dosed nightly for fibromyalgia is supported by the results of TNX-CY-F202 Phase 2b study -- the results provide strong evidence that TNX-102 SL 2.8 mg dosed nightly results in beneficial effects upon pain, sleep and other FM symptomatology.

NCT ID: NCT02829723 Terminated - Clinical trials for Advanced Solid Tumors

A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors

Start date: October 21, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this first-in-human (FIH) study of BLZ945 given as a single agent or in combination with PDR001 was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and anti-tumor activity of BLZ945, administered orally, as a single agent or in combination with PDR001, administered intravenously (i.v.) in adult patients with advanced solid tumors.

NCT ID: NCT02829372 Terminated - Clinical trials for HER2 Expressing Solid Tumours

Phase 1 Study of Single Agent GBR 1302 in Subjects With HER2 Positive Cancers

GBR 1302-101
Start date: May 2016
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety profile and maximum tolerable dose (MTD) of GBR 1302 monotherapy in subjects with HER2 positive cancers

NCT ID: NCT02829047 Terminated - Constipation Clinical Trials

Tolerability, Safety and Efficacy of a New Frequency of Vibrant Capsule Administration

Start date: August 2016
Phase: N/A
Study type: Interventional

The study is a prospective, multicenter, open-label, single-arm study, to evaluate the tolerability, safety and efficacy of the Vibrant Capsule in relieving constipation.